Charles Schwab Investment Management Inc Instil Bio, Inc. Transaction History

Charles Schwab Investment Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 08, 2023	SELL	$0.4 - $0.63 $125,194 - $197,180	-312,985 Reduced 84.0%	59,627 $25,000
Q2 2023 Aug 09, 2023	SELL	$0.51 - $0.67 $48,068 - $63,148	-94,252 Reduced 20.19%	372,612 $204,000
Q1 2023 May 11, 2023	BUY	$0.6 - $0.91 $13,231 - $20,067	22,052 Added 4.96%	466,864 $308,000
Q4 2022 Feb 13, 2023	SELL	$0.48 - $5.33 $12,624 - $140,189	-26,302 Reduced 5.58%	444,812 $280,000
Q3 2022 Nov 14, 2022	BUY	$4.65 - $7.37 $1.14 Million - $1.8 Million	244,824 Added 108.19%	471,114 $2.28 Million
Q2 2022 Aug 15, 2022	BUY	$4.21 - $11.15 $77,960 - $206,475	18,518 Added 8.91%	226,290 $1.05 Million
Q1 2022 May 13, 2022	BUY	$8.48 - $18.1 $55,671 - $118,826	6,565 Added 3.26%	207,772 $2.23 Million
Q4 2021 Feb 11, 2022	BUY	$15.37 - $22.5 $1.23 Million - $1.8 Million	80,033 Added 66.05%	201,207 $3.44 Million
Q3 2021 Nov 16, 2021	BUY	$15.05 - $23.28 $41,221 - $63,763	2,739 Added 2.31%	121,174 $2.17 Million
Q2 2021 Aug 16, 2021	BUY	$15.31 - $24.63 $1.81 Million - $2.92 Million	118,435 New	118,435 $2.29 Million

1.9M

Ticker TIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,694,000
Market Cap $3.39B
Description
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small ce...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.